NCT04879121
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 16 Years and older (Child, Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patient must have received prior standard therapy
Exclusions: Patients with known, symptomatic, unstable brain metastases requiring steroids
https://ClinicalTrials.gov/show/NCT04879121